Salvatore Alesci

Chief Tech/Sci/R&D Officer at

Invea Therapeutics, Inc.

53 year

18 connections

Health Technology

Consumer Services

Commercial Services

Profile

Salvatore Alesci currently works at Invea Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. Alesci also formerly worked at National Foundation for Celiac Awareness, as Chief Scientist & Strategy Officer from 2020 to 2023, InveniAI LLC, as Chief Scientific Officer in 2021, and Takeda Pharmaceutical Co., Ltd., as Vice President & Head-Scientific Affairs from 2015 to 2019.
Dr. Alesci received his doctorate degree from the University of Messina.

Salvatore Alesci active positions

Companies	Position	Start
Invea Therapeutics, Inc. Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs	Chief Tech/Sci/R&D Officer	01/01/2022

All active positions of Salvatore Alesci

Former positions of Salvatore Alesci

Companies	Position	End
National Foundation for Celiac Awareness National Foundation for Celiac Awareness Miscellaneous Commercial ServicesCommercial Services Operates foundations for raising awareness of celiac disease and gluten sensitivity	Corporate Officer/Principal	01/10/2023
Inveniai LLC Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan.	Corporate Officer/Principal	01/12/2021
TAKEDA PHARMACEUTICAL COMPANY LIMITED	Corporate Officer/Principal	01/09/2019

See the detail of Salvatore Alesci's experience

Training of Salvatore Alesci

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Salvatore Alesci's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Takeda Pharmaceutical Co., Ltd. Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products	Health Technology
University of Messina University of Messina Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
National Foundation for Celiac Awareness National Foundation for Celiac Awareness Miscellaneous Commercial ServicesCommercial Services Operates foundations for raising awareness of celiac disease and gluten sensitivity	Commercial Services
Invea Therapeutics, Inc. Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs	Health Technology
Inveniai LLC Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan.	Technology Services